Brief: Syndax Pharmaceuticals Q1 EPS USD -0.85
08/05/2024 12:06
May 08 (Reuters) - Syndax Pharmaceuticals Q1 net income USD -72.4 million. * Q1 operating income USD -79.514 million * Q1 operating expenses USD 79.514 million * Q1 cash & investments USD 522 million
Recent news on Syndax Pharmaceuticals
See all newsBrief: Syndax Announces Topline Results From Maxpire Phase 2 Trial Of Axatilimab In Idiopathic Pulmonary Fibrosis
Syndax says mid-stage trial of lung disease treatment fails main goal, ends development
Syndax Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Syndax Q2 revenue jumps 92% on Revuforj, Niktimvo demand
Brief: Syndax Pharmaceuticals Q2 Operating Income USD -39.995 Million